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Controlled functional expression of 
the bacteriocins pediocin PA-1 and 
bactofencin A in Escherichia coli
Beatriz Mesa-Pereira1,2, Paula M. O’Connor1,2, Mary C. Rea1,2, Paul D. Cotter  1,2, Colin Hill2,3 
& R. Paul Ross1,2,3
The bacteriocins bactofencin A (class IId) and pediocin PA-1 (class IIa) are encoded by operons with 
a similarly clustered gene organization including a structural peptide, an immunity protein, an 
ABC transporter and accessory bacteriocin transporter protein. Cloning of these operons in E. coli 
TunerTM (DE3) on a pETcoco-2 derived vector resulted in successful secretion of both bacteriocins. 
A corresponding approach, involving the construction of vectors containing different combinations 
of these genes, revealed that the structural and the transporter genes alone are sufficient to permit 
heterologous production and secretion in this host. Even though the accessory protein, usually 
associated with optimal disulfide bond formation, was not required for bacteriocin synthesis, its 
presence did result in greater pediocin PA-1 production. The simplicity of the system and the fact that 
the associated bacteriocins could be recovered from the extracellular medium provides an opportunity 
to facilitate protein engineering and the overproduction of biologically-active bacteriocins at industrial 
scale. Additionally, this system could enable the characterization of new bacteriocin operons where 
genetic tools are not available for the native producers.
Antimicrobial peptides (AMPs) are produced by numerous organisms including many Gram-positive bacteria 
as a part of their innate defenses1, 2. AMPs secreted by Lactococcus, Lactobacillus, Pediococcus and other genera of 
lactic acid bacteria (LAB), have attracted considerable attention due to their activity against spoilage and patho-
genic bacteria3. Several of these peptides have proven applications as natural preservatives in the food industry or 
have potential as alternatives to antibiotics in veterinary and medical applications4–6. These bacterial AMPs, also 
called bacteriocins, comprise a heterogeneous family of gene-encoded, small ribosomally synthesized peptides 
with a narrow or broad inhibitory spectrum2, 7.
According to Cotter et al.4, bacteriocins are classified into those which are either post-translationally modified 
(class I) and unmodified or minimally modified peptides (class II)2, 5. Class II bacteriocins are further subdivided 
into pediocin-like bacteriocins (class IIa), two-peptide bacteriocins (class IIb), circular bacteriocins (class IIc) and 
those that cannot be assigned to any of the other bacteriocin subgroups (class IId)2, 8. Class IIa bacteriocins are 
the most extensively studied and are characterized by their strong inhibitory effect on Listeria sp.9, with pediocin 
PA-1 being the best-known of this class.
Generally, the production of class II bacteriocins requires several genes clustered into one or more oper-
ons encoded either on plasmids or on the chromosome. A typical gene cluster consists of a structural gene that 
encodes the prepeptide (or two structural genes for the two-peptide bacteriocins), and individual genes that 
encode an immunity protein, an ATP-binding cassette (ABC) transporter, an accessory protein for extracellular 
translocation of the bacteriocin, and in several cases, two regulatory proteins10. Bacteriocins are usually riboso-
mally synthesized as inactive prepeptides with an N-terminal leader sequence which is attached to a C-terminal 
propeptide. The leader peptide is often cleaved at a double-glycine proteolytic processing site during export by 
an ABC transporter and the mature peptide is released into the external environment. However, a few bacteri-
ocins contain an N-terminal sec-dependent sequence leader and are secreted by general sec-dependent export 
systems11–13.
Characterization of bacteriocins and assessment of their applications often requires that they are obtained 
in a pure form from the culture medium or by chemical synthetic production. However, bacteriocin yields from 
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the native host are often very low and the methods involved in their purification and chemical synthesis can be 
laborious and expensive14–16. The development of heterologous expression systems for bacteriocin production in 
different hosts such as E. coli, LAB and yeasts offers several advantages over native systems, including increased 
production levels, control of bacteriocin gene expression and characterization of bacteriocin systems from genera 
or species where there are no genetic tools available17–19. Compared to other hosts, E. coli is attractive because of 
its extensive genetic characterization and the availability of versatile cloning tools and expression systems. Indeed, 
there are many examples of the cloning of genes involved in the biosynthesis of class II bacteriocins in E. coli, such 
as mesentericin Y10520, gassericin A21, piscicolin 12622, pediocin PA-1 and AcH23–27, divercin V4117, 27, 28, entero-
cin A29, enterocin P30, enterocin CRL3531 and sakacin P16. However, there can also be some limitations to using 
E. coli as an expression host for LAB bacteriocins due to its different genetic background and its limited ability to 
facilitate extensive disulfide bond formation17, 32. To avoid the differences in codon usage that can impede trans-
lation due to the demand for tRNAs that are rare or lacking in the expression host, many bacteriocins have been 
expressed as optimized sequences, replacing the rare codons with synonymous codons, fused to a secretion signal 
sequence to deliver them to the cytoplasm or expressed in E. coli RosettaTM strains which supply tRNAs for the six 
codons rarely used in E. coli31. Bacteriocins have also been expressed as thioredoxin fusion proteins in trxB/gor 
mutant (a thioredoxin reductase and gluthatione reductase knockout) E. coli to enhance solubility and the estab-
lishment of disulfide bonds17, 22. However, using bacteriocin fusion proteins requires an additional cleavage step 
and further purification to access the mature bacteriocin.
Here, we report the heterologous expression of two disulphide bond-containing class II bacteriocins, the 
recently described class IId bactofencin A8 and the well-known class IIa pediocin PA- 133, directly into the 
medium, by cloning their native genes from the natural producers without additional trx gen or signal secretion 
sequences. This represents the first report of bactofencin A production in a Gram-negative organism. In addition, 
we identify the minimum gene cluster required for the expression of the respective bacteriocins in E. coli and 
open up new perspectives for the biotechnological production and modification of these and other bacteriocins.
Results
Cloning of bactofencin A (bfn) and pediocin PA-1 (ped) gene clusters in E. coli. Bactofencin A, 
produced by Lactobacillus salivarius DPC6502, is a highly basic 22-amino-acid peptide containing an intra-
molecular disulfide bond between Cys7 and Cys22 (Fig. 1a), with activity against pathogenic species includ-
ing Staphylococcus aureus and Listeria monocytogenes8. Pediocin PA-1 is a 44 amino acid peptide with a strong 
anti-Listeria activity containing four cysteine residues which form two disulfide bonds between Cys9 and Cys14 
and between Cys24 and Cys44 (Fig. 1b)33 produced by several strains of Pediococcus and Lactobacillus species15.
Initial attempts to express bactofencin A in E. coli under a constitutive promoter were unsuccessful in 
that growth of the bacterium was retarded and the plasmid was rapidly lost. To circumvent this problem, the 
bactofencin A gene cluster (4,110 bp) from Lb. salivarius DPC6502 and the pediocin PA-1 (3,386 bp) operon from 
Pediococcus acidilactici LMG 2351 and different combinations of the genes within these operons were cloned 
into pMPB1 (Figs S1 and S2), a modified pETcocoTM-2 (Novagen) vector. The plasmid pETcocoTM-2 has been 
designed for cloning and expression of toxic proteins through dual control of expression: at transcriptional level 
by the T7 phage promoter inducible by IPTG, and for amplification at the DNA replication level by L-arabinose34. 
To generate the bactofencin A- and pediocin PA-1-operon containing plasmids, the genes of interest were ampli-
fied by PCR, assembled and joined with restriction enzyme-digested pMPB1 vector by an In-Fusion reaction. 
Through this process the entire bactofencin A (pMPB1-bfnAbfnIDLSL_0052DLSL_0053) and pediocin PA-1 
(pMPB1-pedApedBpedCpedD) gene clusters were successfully cloned under the control of T7lac promoter. In 
order to evaluate the effect of the expression of one or more genes on heterologous bacteriocin production, 16 
chimeric plasmids containing different combinations of genes were constructed (Table 1, Fig. S2).
Figure 1. Amino acid sequence of (a) pre-bactofencin A and (b) pre-pediocin PA-1 and the mature sequences 
formed after processing of the leader peptide and oxidation of the cysteines. The black arrow indicates the leader 
peptide cleavage site.
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Induction conditions for bactofencin A and pediocin PA-1 expression in E. coli. To determine the 
optimum time required for bacteriocin production using the T7lac promoter system, E. coli TunerTM (DE3) cells 
carrying the control plasmid (pMPB1) and bfn vector (pMPB1-bfnAbfnIDLSL_0052DLSL_0053) were grown in 
the presence of glucose (low-copy state (LC)) or arabinose (medium-copy state (MC)). Since IPTG concentra-
tions above 100 µM compromised the growth of the producer strains after 24 hours (data not shown), the time for 
optimum production was determined by collecting samples each hour for 8 hours and at 24 hours in the presence 
of 25 µM of IPTG. The results showed bactofencin A activity between 2 and 8 hours after induction in LC condi-
tions and between 1 and 4 hours in the MC state (Fig. S3). Therefore, subsequent experiments were performed 
following 3 hours of induction to ensure bacteriocin expression.
To control both plasmid copy number and expression, E. coli TunerTM (DE3) cells transformed with the 
control plasmid, bfn and ped (pMPB1-pedApedBpedCpedD) vectors, were grown in LB supplemented with 
glucose or arabinose for 3 hours in the presence of 0, 25, 50, 75 and 100 µM of IPTG. The results demonstrate 
Strain or 
plasmid Characteristics
Reference/
source
Strains
Listeria 
innocua 
DPC3572
Indicator organism 52
Lactobacillus 
salivarius 
DPC6502
Bactofencin A producer 52
Pediococcus 
acidilactici 
LMG2351
Pediocin PA-1 producer 53
Lactobacillus 
delbrueckii 
subsp. 
bulgaricus 
LMG6901
Indicator organism LMG
Escherichia 
coli HST08 
StellarTM strain
F−, endA1, supE44, thi-1, recA1, 
relA1, gyrA96, phoA, Φ80d lacZΔ 
M15, Δ (lacZYA - argF) U169, Δ 
(mrr - hsdRMS - mcrBC), ΔmcrA, 
λ−
Takara Bio 
USA
Escherichia coli 
BL21 TunerTM 
(DE3) strain
F− ompT hsdSB (rB− mB−) gal dcm 
lacY1 (DE3) Novagen
Plasmids
pETcocoTM-2
Plasmid with dual controls for 
amplification (araC-PBAD promoter) 
and expression (T7lac promoter). 
Apr.
Novagen34
APC2313 pMPB1, pETcoco
TM-2 with a 
modified MCS. Apr. This work
APC2315 pMPB1- bfnAbfnIDLSL_0052DLSL_0053. Apr. This work
APC2316 pMPB1-bfnA. Apr. This work
APC2317 pMPB1- bfnAbfnI. Apr. This work
APC2318 pMPB1- bfnAbfnIDLSL_0052. Apr. This work
APC2319 pMPB1- bfnIDLSL_0052DLSL_0053. Apr. This work
APC2320 pMPB1- bfnAbfnIDLSL_0053. Apr. This work
APC2321 pMPB1- bfnADLSL_0052DLSL_0053. Apr. This work
APC2322 pMPB1- bfnADLSL_0052. Apr. This work
APC2323 pMPB1- bfnADLSL_0053. Apr. This work
APC2658 pMPB1- pedApedBpedCpedD. Apr. This work
APC2659 pMPB1-pedA. Apr. This work
APC2660 pMPB1- pedApedB. Apr. This work
APC2661 pMPB1- pedApedBpedC. Apr. This work
APC2662 pMPB1- pedBpedCpedD. Apr This work
APC2663 pMPB1- pedApedBpedD. Apr This work
APC2664 pMPB1- pedApedCpedD. Apr This work
APC2665 pMPB1-pedApedC. Apr This work
APC2666 pMPB1- pedApedD. Apr This work
Table 1. Bacterial strains and plasmids used in this work. *MCS, Multiple Cloning site. Apr, ampicillin resistant, 
LMG, Laboratorium voor Microbiologie Culture Collection, Ghent, Belgium.
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that the expressed bactofencin A in the cell-free extracellular fraction is biologically active against the indicator 
Lactobacillus delbrueckii subsp. bulgaricus LMG6901 in both low copy (LC2) and medium copy (MC2) states 
under the IPTG assay concentrations (Fig. 2a). The MC2 condition also showed an inhibitory zone when the sys-
tem was not induced, suggesting a basal bactofencin A expression level. However, the activity of supernatants in 
the presence of IPTG was lower than those expressed at LC at the same IPTG concentration. As shown in Fig. 2b, 
the production of active pediocin PA-1 against Listeria innocua DPC3572 was only achieved at low copy level 
(LC3), increasing from 25 µM to 50 µM IPTG concentration.
Taken together, these results demonstrate the production of active bactofencin A and pediocin PA-1 directly 
into the extracellular medium by E. coli TunerTM (DE3), with the low copy state being the most suitable condition 
for the expression of both bacteriocins. In addition, 25 µM IPTG was selected for the induction of bacteriocin 
production as it was the lowest concentration that showed activity.
Expression of the bacteriocin transporter genes is essential for bfn and ped activity in E. 
coli. Bfn and ped operons are composed of four genes that encode the structural peptide (bfnA, pedA), the 
immunity protein (bfnI, pedB), an ABC transporter (DLSL_0052, pedD) and an accessory protein (DLSL_0053, 
pedC). To determine the genes required for heterologous bacteriocin production, two different groups of plasmids 
were constructed, vectors from which had each gene individually deleted and vectors designed to express the 
structural gene in the presence of the immunity, transporter or accessory encoded genes.
The results revealed that the cell-free supernatants contained active antimicrobials exclusively in the presence 
of the transporters but independent of the presence of the accessory gene in both cases (Fig. 3). Interestingly, 
small zones of inhibition were also observed in the lysates of bfn constructions containing the structural gene 
alone or in combination with the DLSL_0053 gene (Fig. 3a). In the case of pediocin PA-1, only the lysate of the 
strain containing the whole ped operon showed activity (Fig. 3b).
The quantification of the relative extracellular bactofencin A activity produced by bfn constructs was 2-fold 
higher (640 BU/ml) than that produced by the whole bfn operon under the conditions assayed (Fig. 4a). By con-
trast, the pediocin PA-1 constructions showed the same production level in the whole operon vector and pedB 
mutant (160 BU/ml) and a 2-fold reduction in pedC and pedCD mutants (Fig. 4b), indicating that pedC is proba-
bly involved in the optimal activation of pediocin PA-1 produced by E. coli. Although the amount of bactofencin 
A and pediocin PA-1 produced by E. coli was found to be 4 and 8-fold lower than the bacteriocin produced by an 
overnight culture of the natural producers, it should be noted that this level of bacteriocin production in E. coli 
is reached in only 3 hours. In addition, these results suggest that the bactofencin A operon can be simplified for 
heterologous expression, requiring only the transporter gene and the structural gene itself.
Purification of the active bfn and ped supernatants from E. coli and MALDI TOF mass spec-
trometry analysis of bacteriocin. The sequence analysis of DLSL_0053 (bactofencin A transport acces-
sory gene) revealed the presence of the cd02947, a thioredoxin family domain, suggesting that this protein is 
involved in disulfide bond formation. To evaluate the presence of a disulfide bond in the active bfn, the superna-
tants from the natural producer Lb. salivarius and TunerTM(DE3) E. coli carrying the control plasmid, the entire 
bfn operon, and the constructs without the accessory gene (pMPB1- bfnAbfnIDLSL_0052), the immunity gene 
(pMPB1- bfnADLSL_0052DLSL_0053) and without both (pMPB1- bfnADLSL_0052) were purified and analysed 
for the presence of bactofencin A by matrix-assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS) in positive ion reflectron mode. Interestingly, the results showed that all fractions, with the 
exception of the negative control, contained the 2,782 Da bactofencin A mass, indicating that the intramolecular 
disulfide bond formed in all cases, independent of the presence of the accessory gene (Fig. 5a).
Figure 2. Production of bactofencin A and pediocin PA-1 in E. coli. Antibacterial activity of (a) bactofencin 
A and (b) pediocin PA-1 produced by supernatants of E. coli TunerTM (DE3) carrying the control (LC1, MC1), 
bfn (LC2, MC2) and ped (LC3, MC3) vectors at different levels of plasmid amplification (low copy (LC) and 
medium copy (MC)) with 0, 25, 50, 75 and 100 µM of IPTG after 3 h of induction. Lb. bulgaricus LMG6901and 
L. innocua DPC3572 were used as the indicator strains for bactofencin A and pediocin PA-1 activity, 
respectively.
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MALDI TOF analysis in reflectron mode was also used to confirm the presence of both disulphide bonds in 
pediocin PA-1 constructs but the concentration of sample pMPB1-pedApedD was too low to successfully detect 
the monoistopic mass of pediocin in this sample. Instead pediocin PA-1 samples were analysed in positive ion 
Figure 3. Antimicrobial activity of cell-free supernatants (SN) and lysates (L) of E. coli TunerTM (DE3) after 
3 hours of 25 µM IPTG induction. (a) Analysis of bactofencin A activity against Lb. bulgaricus and (b) pediocin 
PA-1 activity againt L. innocua. The genes that encode the structural peptide of bactofencin and pediocin are 
indicated in green and purple arrows, respectively. The immunity, the transporter and the accessory protein 
encoded genes are shown in yellow, blue and red arrows. The black arrow indicates the T7lac promoter. Samples 
from the natural producers Lb. salivarius DPC6502 and P. acidilactici LMG2351 are indicated as Bfn and Ped.
Figure 4. Relative quantification of cell-free supernatants (Bacteriocin units (BU)/ml). Antimicrobial activity 
of (a) bactofencin A and (b) pediocin PA-1 produced by E. coli transformed with the plasmids APC2313 
(control), APC2315, APC2318, APC2321 and APC2322, and APC2658, APC2663, APC2664 and APC2666, 
respectively, in comparison with the samples from the natural producers Lb. salivarius DPC6502 (Bfn) and P. 
acidilactici LMG2351 (Ped). *Bacteriocin activity (BU/ml) was calculated as the inverse of the highest dilution 
showing inhibition of indicator strains divided by volume (0.05 ml).
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linear mode where ions were averaged. MALDI TOF MS analysis of pediocin PA-1 fractions from E. coli showed 
that in addition to the expected mass of 4,625 Da, corresponding to the pediocin PA-1 synthesized by the natural 
producer P. acidilactici, a 4641 Da mass, consistent with the oxidation of methionine, was also detected (Fig. 5b).
Increasing the heterologous production of bfn in E. coli. The level of production of active bactofencin 
A using the simplest system, consisting of both structural and transporter genes, was 640 BU/ml under 25 µM 
of IPTG of induction. This corresponds to approximately 25% of the amount synthesized by the natural pro-
ducer Lb. salivarius DPC6502 and prompted investigations to determine if the synthesis of active bacteriocin 
could be improved by increasing the inducer concentration. To do that, E. coli TunerTM (DE3) transformed with 
pMPB1-bfnADLSL_0052 culture, was induced with 100 µM IPTG and the activity of the supernatant analysed 
after 3 h of induction. As shown in Fig. 6, the relative quantity of active bactofencin A in 3 hours reached approx-
imately 50% of that produced by the natural producer in an overnight culture.
Discussion
Bacteriocins produced by LAB offer a great variety of different applications for the food, health and pharmaceuti-
cal industries5, 35. However, the high cost of bacteriocin purification from natural producers, or chemical synthe-
sis, can limit their large-scale production. This has led to the exploration of alternative heterologous expression 
hosts such as E. coli. To achieve high-level production of native bacteriocins in this host it is also necessary to 
express the specialized secretion machinery required for the recognition and processing of their prepeptides. 
However, the use of systems involving, for example, T7 RNA polymerase can result in cellular toxicity arising 
from overexpression of secretion machinery and other integral membrane proteins26. For these reasons, in 
this study pETcocoTM-2 was selected as a backbone vector to overexpress the bactofencin A and pediocin PA-1 
Figure 5. MALDI-TOF mass spectrometry analysis. (a) Soluble extracellular fractions from bactofencin A 
E. coli producers and (b) pediocin PA-1 producers after 3 hours of IPTG induction. Samples from the natural 
producers Lb. salivarius DPC6502 and P. acidilactici LMG2351 are indicated as Bfn and Ped.
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operons. The dual replicon nature of this vector facilitates cloning under the T7lac promoter and expression of 
toxic proteins due to the extremely low basal expression level in the single copy state which promotes the stability 
of recombinant plasmids, while allowing the amplification of plasmid DNA copy number by arabinose induction 
and/or the increase of protein expression by adding IPTG. In this work, the PCR-amplified genes of interest 
from Lb. salivarius DPC6502 and P. acidilactici LMG2351, encoding bactofencin A and pediocin PA-1 operons, 
respectively, were cloned into the linearized pMPB1 vector, based on the commercial plasmid pETcocoTM-2. 
This facilitated the successful generation of stable expression vectors with the entire bfn and ped operons as well 
as the gene-deleted mutants by assembling the remaining genes of interest, avoiding laborious gene inactiva-
tion approaches. In addition, the use of pETcocoTM-2 derived vectors has allowed the identification of the opti-
mal conditions (low copy number and <100 μM IPTG concentration) for each bacteriocin expression without 
compromising bacterial growth. Interestingly, the production of active bacteriocin in the transformed E. coli 
TunerTM (DE3) cells was not proportional to copy number, implying that the bactofencin A antimicrobial activity 
decreased at the medium-copy state and it became undetectable in the pediocin PA-1 constructs. Considering 
that the growth rate of the cultures was similar to the control (data not shown), the induction of plasmid copy 
number seems to interfere with the ability of E. coli to overproduce these bacteriocins. This can be explained by 
many factors, including the structural features of the recombinant gene sequences, the stability and translational 
efficiency of the mRNA, incomplete processing of signal sequences, the metabolic burden on the host strain, the 
capacity of the transport system and the potential toxicity of the bacteriocin14, 36–38. Thus, a low copy vector was 
the most suitable condition for evaluating the expression of both bacteriocins.
Previous genome sequencing of Lb. salivarius DPC 6502 suggested that bactofencin A biosynthesis involves 
four genes bfnA, bfnI, DLSL_0052 and DLSL_0053 organized in a single operon8. In the present work, we obtained 
a full reconstitution of the in vivo synthesis of bactofencin A in a Gram-negative host. TunerTM (DE3) E. coli cells 
harbouring the complete bfn gene cluster successfully inhibited Lb. bulgaricus. Moreover, the analysis of expres-
sion of gene-deleted mutants demonstrated that only the putative ABC transporter (DLSL_0052) is essential for 
bacteriocin export into the extracellular medium. The ABC transporter contains an N-terminal peptidase C39 
domain responsible for the cleavage of double-glycine leader sequences10, 39. In the absence of the transporter, it 
was not possible to detect antimicrobial activity in supernatants, supporting the theory that this protein plays 
an essential role in the processing and secretion of the mature active bacteriocin. In addition, some activity was 
found in the lysate of E. coli carrying plasmids, encoding the single structural peptide together with the putative 
bactofencin A transport accessory protein (DLSL_0053), suggesting that a small amount of prepeptide could be 
processed by proteases present in the host. The sequence analysis of DLSL_0053 revealed the presence of cd02947, 
a thioredoxin family domain involved in the formation of disulfide bonds. However, the DLSL_0053 gene deletion 
proved that this protein is not required for bactofencin A activity in E. coli. The molecular mass of bactofencin A 
from active supernatants detected by MALDI-TOF MS analysis was 2,782 Da in all the vectors including those 
without the transporter accessory gene, indicating the presence of a disulfide bond. Considering this result, it 
could be hypothesized that the processed peptides could go through the periplasm which contains the enzyme 
DsbA which catalyzes disulfide bond formation40.
The present study shows that the production of pediocin PA-1 also requires the presence of the structural gene 
and the ABC transporter. This is in contrast to the results obtained by Venema et al.41 who concluded that PedC 
was also essential for pediocin PA-1 secretion, and supports the results reported by other authors24, 25. However, 
it is of interest to note that the amount of active pediocin produced by E. coli increases in the presence of pedC, 
suggesting that the accessory protein PedC enhances active pediocin PA-1 production in E. coli. These results 
are in accordance with those described previously by Oppegard et al.42 who indicated that PedC is important to 
ensure the correct formation of disulfide bonds in pediocin PA-1. In contrast, MALDI-TOF MS analysis of the 
purified pediocin PA-1 supernatants from E. coli showed an additional peptide fragment of 4,641 Da that is not 
present in the fractions from the natural producer P. acidilactici (4,625 Da). The 16 Da molecular mass difference 
is explained by the oxidation of methionine residues to MetSO during the recombinant production as it has been 
Figure 6. Quantification of the expression of bactofencin A produced by E. coli Tuner (DE3) transformed with 
the plasmid containing the structural and the transporter encoded genes after 3 h of 100 µM ITPG induction. 
The activity of the supernatant from an overnight culture of Lb. salivarius is indicated as Bfn. *Bacteriocin 
activity (BU/ml) was calculated as the inverse of the highest dilution showing inhibition of Lb. bulgaricus 
indicator strain divided by volume (0.05 ml).
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described in other heterologous hosts such as yeasts43, 44 and LABs45–47. To protect the peptide from oxidation, 
Met could be replaced by either Ala, Ile or Leu, with minor effects on the bacteriocin activity48.
In general, overexpressed recombinant proteins in E. coli are accumulated either in the periplasmic space or in 
the cytoplasm in inclusion bodies so additional purification steps are required to obtain pure active peptide49. In 
contrast, we show that the use of derived pETcoco-2 vectors together with the TunerTM (DE3) E. coli host allows 
the expression of active bacteriocins directly into the medium and, therefore, could be used to simplify the puri-
fication process. Remarkably, both secreted bacteriocins contained disulfide bonds, overcoming one of the major 
limitations of disulfide bond production in E. coli.
This is, to our knowledge, the first description of the production of bactofencin A in E. coli and the functional 
analysis of the genes involved in their heterologous production. The analysis revealed that only the structural gene 
and the transporter encoded gene are required for expression of fully functional bacteriocins. Induction with 
100 µM IPTG led to an increase in the bactofencin A production, reaching in 3 hours 50% of the bactofencin A 
produced by the natural producer Lb. salivarius in an overnight culture. Even though the levels of heterologous 
production of bactofencin A and pediocin PA-1 in E. coli were lower than those observed in the natural producer, 
its recovery from the supernatants may be faster, easier and more cost effective.
The results presented here suggest that this system could be useful for expressing new bacteriocin operons 
described in silico as well as their characterization at molecular level when there is no access to the original pro-
ducer strains or the transformation efficiencies of natural producers is a severe impediment for gene analysis, 
opening the door to the heterologous expression and harnessing of the potential of new bacteriocins in the future.
Methods
Bacterial strains, plasmids and culture conditions. Bacterial strains and plasmids used in this study 
are listed in Table 1. Escherichia coli HST08 strain StellarTM (Takara Bio USA, Inc, Mountain View, CA), was 
used for standard cloning procedures and Escherichia coli BL21 strain TunerTM (DE3) (also called E. coli TunerTM 
(DE3)) (Novagen, EMD Millipore, Billerica, MA) was used for gene expression experiments. Escherichia coli 
strains were grown aerobically at 180 r.p.m. and 37 °C in Luria-Bertani (LB) medium and supplemented with 
ampicillin (50 μg/ml) for the selection and maintenance of plasmids. Lactobacillus salivarius DPC6502, used 
as a bactofencin A producer, and the bactofencin A-sensitive strain Lactobacillus delbrueckii subsp. bulgaricus 
LMG6901 (Lb. bulgaricus LMG 6901) were grown under anaerobic conditions at 37 °C in MRS medium (Difco 
Laboratories, Detroit, MI). Anaerobic conditions were maintained with the use of anaerobic jars and Anaerocult 
A gas packs (Merck, Darmstadt, Germany). Pediococcus acidilactici LMG2351, used as a pediocin PA-1 producer, 
was cultured aerobically in MRS broth at 30 °C without shaking. The pediocin PA-1-sensitive indicator strain 
Listeria innocua DPC 3572 was grown aerobically at 37 °C in brain heart infusion (BHI) medium (Merck) without 
shaking. Gene expression was induced by IPTG (isopropyl- β-D-thiogalactopyranoside). IPTG was supplied by 
Fisher Scientific (Dublin, Ireland) dissolved in water, filter sterilized, and added to the media. (D)  + -glucose, 
L- + -Arabinose and other chemical reagents were obtained from Sigma Aldrich (Arklow, Ireland). Pediococcus 
acidilactici LMG2351 was a gift from Dzung Bao Diep, Laboratory of Microbial Gene Technology, Agricultural 
University of Norway, Ås, Norway.
Molecular biology general procedures. All DNA manipulations were performed following standard pro-
tocols50. All oligonucleotides used in this study are described in Supplementary Tables S1 and S2. The plasmid 
pETcocoTM-2 (Novagen) was used for gene construction and expression. Firstly, the multiple cloning site (MCS) 
was replaced by the product of annealing of MCS F SphI and MCS R AvrII primers, digested with SphI-AvrII 
and cloning into pETcocoTM-2 SphI-AvrII, generating plasmid pMPB1 (APC2313). A detailed description of the 
cloning of the bactofencin A and pediocin PA-1 gene fragments into the linearized pMPB1 is provided in the 
Supplementary information. The primers were designed according to the instructions of In-Fusion HD cloning 
and they were obtained from Sigma Aldrich (Arklow, Ireland). Briefly, the bactofencin A and pediocin PA-1 
sequences were amplified by polymerase chain reaction (PCR) using CloneAmp HiFi PCR premix (Takara Bio 
USA, Inc, Mountain View, CA) and genomic DNA from L. salivarius DPC 6502 and plasmid DNA from P. acidi-
lactici LMG2351 were used as DNA templates, respectively. The PCR products were eluted with illustra GFX 
PCR DNA and Gel Band Purification kit (GE Healthcare, Buckinghamshire, UK) and inserted into the linearized 
pMPB1 vector using In-Fusion HD cloning Plus (638910, Takara Bio USA, Inc, Mountain View, CA) as described 
previously51. The constructions were transformed into StellarTM competent cells and colonies were selected on 
plates containing ampicillin 50 μg/ml) and D (+)-glucose (0.2%). The transformants were confirmed by colony 
PCR reactions. Then, the number of copies of the recombinant plasmids was increased by L-arabinose induc-
tion before plasmid DNA isolation was analysed by double digestion and sequencing. All DNA sequencing were 
performed by GATC Biotech (Koln, Germany). The resulting vectors are summarised in the Table 1 and Fig. S2. 
Restriction enzymes and T4 DNA ligase were obtained from New England Biolabs (Ipswich, M). Genomic and 
plasmid DNA were isolated using GenEluteTM Bacterial Genomic DNA kit (Sigma Aldrich, St.Louis, MO) and 
NucleoSpin® plasmid kit (Macherey-Nagel, Duren, Germany), respectively.
Induction of bacteriocin expression. Bactofencin A and pediocin PA-1 production were tested under 
different expression conditions (plasmid copy number and IPTG concentration) in order to find the best condi-
tion to induce bacteriocin production. For this purpose, TunerTM (DE3) E. coli cells were transformed with the 
control vector (pMPB1) and those carrying bfn (pMPB1- bfnAbfnIDLSL_0052 DLSL_0053) and ped operons 
(pMPB1-pedApedBpedCpedD), and isolated colonies were grown in LB broth containing ampicillin (50 μg/ml) 
and 0.2% D(+)-glucose (LBAp50Glc0.2), which maintains the plasmid in a single-copy state, for 16 hours at 37 °C 
with shaking. The cultures were diluted 1:50 into fresh LBAp50Glc0.2 medium to keep the low copy state (LC) 
and fresh LB containing ampicillin (50 μg/ml) and L-+-Arabinose (0.01%) to increase the number of copy of 
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plasmids (Medium Copy state (MC)). When cells reached OD600 0.5–0.6, IPTG was added at concentrations of 0, 
25, 50, 75 and 100 µM and the cultures were incubated for 3 h at 37 °C before determining the antimicrobial effect 
of the supernatants against the indicator strains as described in bacteriocin activity assay.
Bacteriocin activity assay. Bactofencin A and pediocin PA-1 antimicrobial activities were determined by 
the well-diffusion method against the indicator strain L. delbrueckii subsp. bulgaricus LMG6901 and L. innocua 
DPC3572, respectively. Briefly, 5 ml of transformed E. coli cells were centrifuged at 4,000 × g at 4 °C for 15 min-
utes. The bacterial pellets were washed and resuspended in 5 ml of PBS solution and further lysed via sonication 
(5 pulses at 16 W, 15 s/pulse and intervals of 45 s on ice) in a MSE Soniprep 150 (MSE, London, UK) and centri-
fuged at 4,000 × g at 4 °C for 15 min. The resulting cell-free intracellular fraction from the lysate and the cell-free 
supernatant of the cultures were filtered with 0.20 μm membrane filters (Sartorius, Germany). 50 μl of cell-free 
supernatants (SN) and lysates (L) of each culture were applied to 5 mm diameter wells on MRS 1% agar plates 
containing L. delbrueckii subsp. bulgaricus LMG6901 and BHI 0.8% agar plates containing L. innocua DPC3572. 
MRS and BHI agar plates were refrigerated for two hours prior to incubation at 37 °C under anaerobic and aerobic 
conditions, respectively, for 24 hours.
As positive controls of bactofencin A and pediocin PA-1 production, the natural producers L. salivarius 
DPC6502 and P. acidilactici LMG2351 were grown in MRS broth at 37 °C (under anaerobic conditions) and 
30 °C (aerobic conditions) for 16 h, respectively. Cell-free culture supernatants were obtained by centrifugation of 
cultures at 4,000 × g at 4 °C for 15 min. The pH was adjusted to pH 7 using 1 M NaOH to avoid any antimicrobial 
activity caused by the acidity of the cell free supernatants and filtered through 0.20 μm pore-size filters. The pellets 
were sonicated as described previously.
To quantify the relative active bacteriocin production, 50 µl of two-fold serial dilutions of each sample were 
placed in wells. The bacteriocin activity was expressed in bacteriocin units per ml (BU ml−1) and was defined as 
the reciprocal of the highest dilution showing inhibition of the indicator strain.
Purification and MALDI TOF mass spectrometry analysis of bfn and ped. Twenty five ml of culture 
of L. salivarius DPC 6502 and E. coli Tuner DE3 containing the bacteriocin expression plasmids were harvested by 
centrifugation at 4,000 × g at 4 °C for 20 min, the bactofencin A supernatants were applied to a column containing 
2 ml SP Sepharose fast-flow cation-exchange resin (GE Healthcare, United Kingdom), equilibrated with buffer A 
[20 mM potassium phosphate buffer and 25% acetonitrile, pH 2.5]. The column was then washed with buffer A 
and with 10 ml buffer B (buffer A containing 500 mM KCl) and peptides eluted with 10 ml of Buffer C (buffer A 
containing 1000 mM KCl). The 1 M KCl eluents were desalted using C18 SPE zips (Millipore, Cork, Ireland). Zip 
tips were primed by washing with 3 × 10 µl aliquots of 100% acetonitrile followed by 5 × 10 µl aliquots of 0.1% 
TFA. The sample was bound to the zip tip by repeated pipetting of a 50 µl aliquot of sample, the tip was washed 
with 3 × 10 µl aliquots of 0.1% TFA and bactofencin A eluted by repeated pipetting in 3 µl CHCA matrix. Samples 
were analysed for the presence of bactofencin A by MALDI TOF mass spectrometry (Axima- TOF2; Shimadzu 
Biotech, Manchester, United Kingdom) in positive ion reflectron mode.
One hundred ml of pediocin PA-1 samples were applied to 500 mg 6 ml Strata C18-E SPE columns 
pre-equilbrated with methanol and water. The columns were washed with 6 ml 30% ethanol and the samples 
eluted with 6 ml of IPA (70% propan-2-ol, 0.1% TFA). The IPA eluents were analysed by MALDI TOF mass spec-
trometry in positive ion reflectron and linear mode.
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